Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy.

ABSTRACT:

Background

Adolescents with DMD treated with chronic high dose GC therapy typically have profound pubertal delay. Testosterone, the main circulating androgen in men, promotes virilisation and growth with associated accrual of fat-free muscle mass and bone mineral content. Testosterone therapy is routinely used to mimic the normal stages of pubertal development in patients with hypogonadotrophic hypogonadism, androgen deficiency secondary to testicular disease and in constitutional delay of growth and puberty (CDGP). Improved life expectancy in DMD has meant that more adolescents are eligible for testosterone supplementation but there is little objective data regarding the impact of this treatment on muscle structure and function, bone integrity and overall well-being.

Methods

SUBMITTER: Wood CL 

PROVIDER: S-EPMC6482579 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature